VNX001

Phase 2Small molecule

VVaneltix Pharma, Inc.

VNX001 is one of 44 small molecule programs targeting Interstitial Cystitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial CystitisActive, not recruiting

Interstitial CystitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Interstitial Cystitis

#DrugCompanyPhaseTrials

Revia

Pitocin

1 3

Cimzia

UCB

Phase 3

1 4

Xolair

Roche

Phase 3

1 5

Myrbetriq

Astellas

Phase 3

1 6

Intron a

Sanofi

Phase 3

1 7

Humira

CCelltrion

Phase 3

1 8

Sodium Hyaluronate

Sanofi

Phase 3

1 9

Neoral

Novartis

Phase 2

1 10

Quietus

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interstitial Cystitis1 trial

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

Recruiting·VVaneltix Pharma, Inc.·Phase 2·NCT06394830·50 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Recruiting·VVaneltix Pharma, Inc.·Phase 2·NCT05737121·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VNX001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VNX001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VNX001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vaneltix Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVaneltix Pharma, Inc.

VNX001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interstitial Cystitis1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News